<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649477</url>
  </required_header>
  <id_info>
    <org_study_id>LV-101-3-01</org_study_id>
    <nct_id>NCT03649477</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome</brief_title>
  <acronym>CARE-PWS</acronym>
  <official_title>Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Levo Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Levo Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is designed to test the effectiveness of intranasal carbetocin (LV-101) in&#xD;
      participants with Prader-Willi syndrome (PWS). Carbetocin is an oxytocin analog (a man-made&#xD;
      chemical that is like oxytocin). This study will also evaluate the safety and tolerability of&#xD;
      LV-101.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 randomized, double-blind study with an 8-week, placebo-controlled period&#xD;
      designed to test the effectiveness, safety, and tolerability of LV-101 in participants with&#xD;
      PWS.&#xD;
&#xD;
      Effectiveness will be measured using both caregiver-reported and clinician-reported measures&#xD;
      of hyperphagia (extreme hunger), obsessive and compulsive behaviors, and anxiety. Safety and&#xD;
      tolerability will be measured by adverse events, laboratory tests, and physical exams.&#xD;
&#xD;
      After the 8-week placebo-controlled period, there will be a long-term follow-up period of 56&#xD;
      weeks and an optional extension period after study week 64 during which all participants will&#xD;
      receive active treatment with LV-101. At Week 8, participants who were randomized to placebo&#xD;
      in the placebo-controlled period will be randomized to one of the two LV-101 doses,&#xD;
      administered three times per day before meals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 20, 2018</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 13, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Three parallel groups (two different doses of carbetocin and placebo) for the first 8 weeks; two parallel groups (two different doses of carbetocin) during 56 weeks of follow-up and the optional extension period</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hyperphagia Behavior</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change in hyperphagia (extreme hunger) as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score versus placebo.&#xD;
Score range: 0-36; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Obsessive and Compulsive Behaviors</measure>
    <time_frame>baseline to Week 8</time_frame>
    <description>Change in obsessive and compulsive behaviors as measured by the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) Total Score versus placebo.&#xD;
Score range: 0-40; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change in participant anxiety as measured by the PWS Anxiety and Distress Questionnaire (PADQ) Total Score versus placebo.&#xD;
Score range: 0-56; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Impression</measure>
    <time_frame>Week 8</time_frame>
    <description>Clinical Global Impression of Change (CGI-C) score versus placebo. Score range: 1-7; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperphagia Behavior (Subset)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Change in hyperphagia as measured by the change in specified subsets of HQ-CT questions versus placebo.&#xD;
Score range: 0-24; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Prader-Willi Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo during first 8-weeks; prospectively randomized 1:1 to either one of the two doses of carbetocin during 56-week follow-up and optional extension periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3.2 mg of LV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.2 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9.6 mg of LV-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9.6 mg of LV-101 during first 8-weeks; remain on same dose during 56-week follow-up and optional extension periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3.2 mg intranasal carbetocin</intervention_name>
    <description>three times per day with meals</description>
    <arm_group_label>3.2 mg of LV-101</arm_group_label>
    <other_name>LV-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>9.6 mg intranasal carbetocin</intervention_name>
    <description>three times per day with meals</description>
    <arm_group_label>9.6 mg of LV-101</arm_group_label>
    <other_name>LV-101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>three times per day with meals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Genetically-confirmed Prader-Willi syndrome&#xD;
&#xD;
          -  Provide voluntary, written informed consent (parent(s) / legal guardian(s) of&#xD;
             participant); provide voluntary, written assent (participants, as appropriate)&#xD;
&#xD;
          -  PWS Nutritional Phase 3 (hyperphagic, rarely feels full)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Living in a group home&#xD;
&#xD;
          -  Genetically diagnosed Schaaf-Yang syndrome or other genetic, hormonal, or chromosomal&#xD;
             cognitive impairment&#xD;
&#xD;
          -  New food-related interventions, including environment or dietary restrictions, within&#xD;
             1 month of screening&#xD;
&#xD;
          -  Dose of any allowed chronic concomitant medications or supplements that have not been&#xD;
             stable for ≥3 months prior to the study or is not expected to remain stable while&#xD;
             participating in the study; adjustments in growth hormone dose ≤10% are not&#xD;
             exclusionary&#xD;
&#xD;
          -  Presence of cardiovascular disorders, epilepsy, frequent migraines, or severe asthma&#xD;
&#xD;
          -  More than 3 episodes of sinusitis in the 12 months prior to Screening Visit or&#xD;
             presence of nasal diseases that may affect deposition of intranasal medication&#xD;
&#xD;
          -  Unwilling to abstain from nasal saline, other nasal irrigation, or other intranasal&#xD;
             medications for 2 weeks prior to the Baseline visit and during the 8-week,&#xD;
             placebo-controlled period of the study&#xD;
&#xD;
          -  Use of weight loss medication, oxytocin, carbetocin, or vasopressin in the 6 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Participation in an interventional research study involving another investigational&#xD;
             medication or device in the 6 months prior to screening or during the study&#xD;
&#xD;
          -  Based on the judgment of the Investigator, is unsuitable for the study for any reason,&#xD;
             including but not limited to unstable medical condition, inability to comply with the&#xD;
             protocol, or other risk to subject or to the integrity of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Los Angeles (USC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ann &amp; Robert H. Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Harvard Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospitals and Clinics of Minnesota</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University School of Medicine</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queensland Children's Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Hospital for Sick Kids</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Ste Justine</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.levotx.com/care-pws/</url>
    <description>Levo CARE-PWS Study</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 24, 2018</study_first_submitted>
  <study_first_submitted_qc>August 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <results_first_submitted>August 30, 2021</results_first_submitted>
  <results_first_submitted_qc>October 19, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 17, 2021</results_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PWS</keyword>
  <keyword>Prader-Willi syndrome</keyword>
  <keyword>carbetocin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prader-Willi Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03649477/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT03649477/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled in three countries, the United States, Canada and Australia. The first participant was screened in November 2018, the first participant was enrolled in December 2018, and the last participant was enrolled in March 2020.</recruitment_details>
      <pre_assignment_details>Subjects were randomized 1:1:1 at Baseline to receive the 9.6 mg/dose, 3.2 mg/dose, or placebo during the 8-week placebo-controlled period. A total of 130 subjects were evaluated (44 subjects in the 9.6 mg/dose arm, and 43 subjects each in the 3.2 mg/dose and placebo arms). Of these 130 subjects, 128 subjects (98.5%) completed the Week 8 visit and entered into the long-term follow-up period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>9.6 mg of LV-101</title>
          <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="P2">
          <title>3.2 mg of LV-101</title>
          <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>9.6 mg of LV-101</title>
          <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="B2">
          <title>3.2 mg of LV-101</title>
          <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="43"/>
            <count group_id="B4" value="130"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Inclusion criteria was 7 to 18 years of age at Screening. Subjects who were 19 years of age at Baseline were still eligible to participate if all other eligibility criteria were met.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hyperphagia Behavior</title>
        <description>Change in hyperphagia (extreme hunger) as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score versus placebo.&#xD;
Score range: 0-36; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
        <group_list>
          <group group_id="O1">
            <title>9.6 mg of LV-101</title>
            <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O2">
            <title>3.2 mg of LV-101</title>
            <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperphagia Behavior</title>
          <description>Change in hyperphagia (extreme hunger) as measured by the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Total Score versus placebo.&#xD;
Score range: 0-36; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
          <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.439" lower_limit="-5.304" upper_limit="-1.575"/>
                    <measurement group_id="O2" value="-5.372" lower_limit="-7.259" upper_limit="-3.486"/>
                    <measurement group_id="O3" value="-2.237" lower_limit="-4.095" upper_limit="-0.378"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3493</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.202</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.729</ci_lower_limit>
            <ci_upper_limit>1.324</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0162</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.685</ci_lower_limit>
            <ci_upper_limit>-0.586</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Obsessive and Compulsive Behaviors</title>
        <description>Change in obsessive and compulsive behaviors as measured by the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) Total Score versus placebo.&#xD;
Score range: 0-40; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
        <time_frame>baseline to Week 8</time_frame>
        <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
        <group_list>
          <group group_id="O1">
            <title>9.6 mg of LV-101</title>
            <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O2">
            <title>3.2 mg of LV-101</title>
            <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Obsessive and Compulsive Behaviors</title>
          <description>Change in obsessive and compulsive behaviors as measured by the Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) Total Score versus placebo.&#xD;
Score range: 0-40; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
          <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.968" lower_limit="-4.667" upper_limit="-1.268"/>
                    <measurement group_id="O2" value="-3.123" lower_limit="-4.843" upper_limit="-1.403"/>
                    <measurement group_id="O3" value="-2.360" lower_limit="-4.046" upper_limit="-0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6001</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.608</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.890</ci_lower_limit>
            <ci_upper_limit>1.674</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5143</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.764</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.068</ci_lower_limit>
            <ci_upper_limit>1.541</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anxiety</title>
        <description>Change in participant anxiety as measured by the PWS Anxiety and Distress Questionnaire (PADQ) Total Score versus placebo.&#xD;
Score range: 0-56; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
        <group_list>
          <group group_id="O1">
            <title>9.6 mg of LV-101</title>
            <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O2">
            <title>3.2 mg of LV-101</title>
            <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Anxiety</title>
          <description>Change in participant anxiety as measured by the PWS Anxiety and Distress Questionnaire (PADQ) Total Score versus placebo.&#xD;
Score range: 0-56; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
          <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.306" lower_limit="-6.797" upper_limit="-1.815"/>
                    <measurement group_id="O2" value="-8.301" lower_limit="-10.790" upper_limit="-5.811"/>
                    <measurement group_id="O3" value="-4.489" lower_limit="-6.942" upper_limit="-2.037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9144</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.183</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.175</ci_lower_limit>
            <ci_upper_limit>3.541</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-3.812</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.177</ci_lower_limit>
            <ci_upper_limit>-0.446</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Impression</title>
        <description>Clinical Global Impression of Change (CGI-C) score versus placebo. Score range: 1-7; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
        <time_frame>Week 8</time_frame>
        <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
        <group_list>
          <group group_id="O1">
            <title>9.6 mg of LV-101</title>
            <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O2">
            <title>3.2 mg of LV-101</title>
            <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Global Impression</title>
          <description>Clinical Global Impression of Change (CGI-C) score versus placebo. Score range: 1-7; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
          <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.582" lower_limit="3.250" upper_limit="3.913"/>
                    <measurement group_id="O2" value="3.395" lower_limit="3.057" upper_limit="3.733"/>
                    <measurement group_id="O3" value="3.893" lower_limit="3.562" upper_limit="4.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1598</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.312</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.748</ci_lower_limit>
            <ci_upper_limit>0.125</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0266</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.498</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.937</ci_lower_limit>
            <ci_upper_limit>-0.059</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hyperphagia Behavior (Subset)</title>
        <description>Change in hyperphagia as measured by the change in specified subsets of HQ-CT questions versus placebo.&#xD;
Score range: 0-24; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
        <group_list>
          <group group_id="O1">
            <title>9.6 mg of LV-101</title>
            <description>9.6 mg of LV-101 during the 8-week placebo-controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O2">
            <title>3.2 mg of LV-101</title>
            <description>3.2 mg of LV-101 during the 8-week placebo controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matched intranasal placebo during the 8-week placebo controlled period&#xD;
placebo: three times per day with meals</description>
          </group>
        </group_list>
        <measure>
          <title>Hyperphagia Behavior (Subset)</title>
          <description>Change in hyperphagia as measured by the change in specified subsets of HQ-CT questions versus placebo.&#xD;
Score range: 0-24; higher scores mean a worse outcome. Reduction in score indicates improvement.</description>
          <population>Primary Analysis Set: A subset of the Full Analysis Set that included all subjects with at least one post-Baseline visit (i.e., Week 2 or Week 8) completed prior to March 01, 2020 and excluded all efficacy data collected on or after March 01, 2020.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
                <count group_id="O3" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.295" lower_limit="-4.667" upper_limit="-1.922"/>
                    <measurement group_id="O2" value="-4.621" lower_limit="-6.010" upper_limit="-3.233"/>
                    <measurement group_id="O3" value="-2.209" lower_limit="-3.577" upper_limit="-0.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2479</p_value>
            <p_value_desc>0.05 threshold for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.085</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.932</ci_lower_limit>
            <ci_upper_limit>0.761</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0114</p_value>
            <p_value_desc>0.05 for statistical significance</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.412</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.276</ci_lower_limit>
            <ci_upper_limit>-0.548</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-week placebo-controlled period</time_frame>
      <group_list>
        <group group_id="E1">
          <title>9.6 mg of LV-101</title>
          <description>9.6 mg of LV-101 during the 8-week placebo controlled period&#xD;
9.6 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="E2">
          <title>3.2 mg of LV-101</title>
          <description>3.2 mg of LV-101 during the 8-weeks placebo-controlled period&#xD;
3.2 mg intranasal carbetocin: three times per day with meals</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matched intranasal placebo during 8-week placebo-controlled period&#xD;
placebo: three times per day with meals</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="44"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="43"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>This study is a multi-center study. Sponsor retains first publication rights for a period of time after conclusion of study. Study has not yet completed.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The COVID-19 pandemic began affecting this study in early March 2020 by substantially impacting the ability to safely enroll clinical study subjects, by requiring remote visits and monitoring, and by dramatically changing daily routines and social environments in this sensitive PWS population. Levo held new screening and enrollment in March 2020, and subsequently closed screening and enrollment in May 2020, resulting in the enrollment of 130 subjects instead of the 175 subjects planned.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President of Clinical Development</name_or_title>
      <organization>Levo Therapeutics</organization>
      <phone>1-847-901-9260</phone>
      <email>contactus@levotx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

